Article
Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.
British journal of cancer - 1 Nov 2022
Liu Chunnan, Liu Zhaopei, Jin Kaifeng, Zeng Han, Shao Fei, Chang Yuan, Wang Yiwei, Xu Le, Wang Zewei, Zhu Yu, Zhang Weijuan
Abstract excerpt
BACKGROUND: CD39, a rate-limiting enzyme to convert extracellular ATP (eATP) to adenosine, has been reported to be a key modulator of immune response, but its correlation with therapeutic sensitivity remains obscure. We conducted this study to determine whether the integration of CD39 and traditional biomarkers could improve the prediction of responsiveness to PD-L1 blockade and platinum-based chemotherapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.